EN

王帅有机化学,青年副研究员

  • 研究兴趣

  • 学术任职

  • 获奖情况

  • 学习工作经历

  • 授课情况

  • 代表性论文或专著

  • 基于计算机辅助和药物作用机制抗病毒创新药物研究

  • 基于计算机辅助和药物作用机制抗肿瘤创新药物研究

  • 多样性化合物库及新药筛选平台的构建



  • 2010.9-2014.7, 锦州医科大学, 药学院, 学士

  • 2014.9-2017.7, 郑州大学, 药学院, 硕士

  • 2017.9-2021.7, 郑州大学, 药物研究院, 博士

  • 2019.9-2021.2, 哈佛医学院, 戈登医学影像中心, 药物化学专业联合培养博士

  • 2021.7-2022.7, 复旦大学, 化学系, 科研助理

  • 2022.7至今, 复旦大学, 化学系, 青年副研究员

  • 药物化学进展

  • 药物合成化学

  1. Sang,Y. L.; Pannecouque, C.; Clercq, E.; Wang, S.*; Chen, F. E.*, Fragment hopping-based design of novel biphenyl-DAPY derivatives as potent NNRTIs featuring significantly improved anti-resistance efficacy. J. Med. Chem.2023, 66(7), 4755-4767.

  2. Sang,Y. L.; Pannecouque, C.; Clercq, E.; Wang, S.*; Chen, F. E.*, Picomolar inhibitor of reverse transcriptase featuring significantly improved metabolic stability. Acta. Pharm. Sin. B 2023, doi.org/10.1016/j.apsb.2023.03.022.

  3. Zhou, R. L.; Ju, Z.; Pannecouque, C.; Clercq, E.; Wang, S.*; Chen, F. E.*, Structure-guided design of novel HEPT analogs with enhanced potency and safety: From Isopropyl-HEPTs to Cyclopropyl-HEPTs. Eur. J. Med. Chem.2023, 246, 114939.

  4. Ling, X.; Hao, Q. Q.; Huang, W. J.; Pannecouque, C.; De Clercq, E.; Wang, S.*; Chen, F. E.*, Development of novel S-N3-DABO derivatives as potent non-nucleoside reverse transcriptase inhibitors with improved potency and selectivity. Eur. J. Med. Chem.2023, 247, 115042.

  5. Zhao, L. M.; Pannecouque, C.; De Clercq, E.; Wang, S.*; Chen, F. E.*, Structure-directed expansion of biphenyl-pyridone derivatives as potent non-nucleoside reverse transcriptase inhibitors with significantly improved potency and safety. Chin. Chem. Lett.2023, 108261.

  6. Hao, Q. Q.; Chen, X. M.; Pannecouque, C.; De Clercq, E.; Wang, S.*; Chen, F. E.*, Structure-directed linker optimization of novel HEPTs as non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg. Chem. 2023, 133, 106413.

  7. Jin, X.; Wang, S.; Zhao, L. M.; Huang, W. J.; Zhang, Y. X.; Pannecouque, C.; De Clercq, E.; Meng, G.*; Piao, H. R.*; Chen, F.*, Development of fluorine-substituted NH2-biphenyl-diarylpyrimidines as highly potent non-nucleoside reverse transcriptase inhibitors: boosting the safety and metabolic stability. Acta. Pharm. Sin. B2023, 13, 1192-1203.

  8. Jin, X.; Zhao, L. M.; Wang, S.; Huang, W. J.; Zhang, Y. X.; Pannecouque, C.; De Clercq, E.; Chen, F. E.*, Structure-based discovery of novel NH2-biphenyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors with significantly improved safety: from NH2-naphthyl-diarylpyrimidine to NH2-biphenyl-diarylpyrimidine. J. Med. Chem.2022, 65 (12), 8478-8492.

  9. Zhao, L. M.; Wang, S.; Pannecouque, C.; De Clercq, E.; Piao, H. R.*; Chen, F. E.*, Discovery of novel biphenyl-substituted pyridone derivatives as potent non-nucleoside reverse transcriptase inhibitors with promising oral bioavailability. Eur. J. Med. Chem. 2022, 240, 114581.

  10. Hao, Q.; Wang, S.; Huang, W.; Zhang, Y.; Pannecouque, C.; De Clercq, E.; Chen, F.*, Structure-based design of [(2-hydroxyethoxy)methyl]-6-(phenylthio)-thymine derivatives as nonnucleoside HIV-1 reverse transcriptase inhibitors: from HEPTs to sulfinyl-substituted HEPTs. Bioorg. Chem.2022, 126, 105880.

  11. Wang, S.; Chen, F. E.*, Small-molecule MDM2 inhibitors in clinical trials for cancer therapy. Eur. J. Med. Chem.2022, 236, 114334.

  12. Wang, S.1; Wang, S. Q.1; Teng, Q. X.; Lei, Z. N.; Chen, Z. S.; Chen, X. B.*; Liu, H. M.*; Yu, B.*, Discovery of the triazolo[1,5-a]pyrimidine-based derivative WS-898 as a highly efficacious and orally bioavailable ABCB1 inhibitor capable of overcoming multidrug resistance. J. Med. Chem. 2021, 64 (21), 16187-16204.

  13. Wang, S.; Yuan, X. H.; Wang, S. Q.; Zhao, W.; Chen, X. B.; Yu, B.*, FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application. Eur. J. Med. Chem.2021, 214, 113218.  

  14. Wang, S.; Gong, L. C.; El Fakhri, G.*; Wang, J. F.*, Efficient synthesis of 6,6′-diamido-2,2′-dipicolylamine ligands for potential phosphate anion sensing. New J. Chem. 2021, 45 (36), 16833-16840.

  15. Huo, J. L.1; Wang, S.1; Yuan, X. H.; Yu, B.*; Zhao, W.*; Liu, H. M.*, Discovery of [1,2,4]triazolo[1,5-a]pyrimidines derivatives as potential anticancer agents. Eur. J. Med. Chem.2021, 211, 113108.  

  16. Wang, S.1; Shen, D. D.1; Zhao, L. J.1; Yuan, X. H.; Cheng, J. L.; Yu, B.*; Zheng, Y. C.*; Liu, H. M.*, Discovery of [1,2,4]triazolo[1,5-a]pyrimidine derivatives as new bromodomain-containing protein 4 (BRD4) inhibitors. Chin. Chem. Lett. 2020, 31 (2), 418-422.

  17. Wang, S.1; Wang, S. Q.1; Teng, Q. X.1; Yang, L. L.; Lei, Z. N.; Yuan, X. H.; Huo, J. F.; Chen, X. B.; Wang, M. R.; Yu, B.*; Chen, Z. S.*; Liu, H. M.*, Structure-based design, synthesis, and biological evaluation of new triazolo[1,5-a]pyrimidine derivatives as highly potent and orally active ABCB1 modulators. J. Med. Chem.2020, 63 (24), 15979-15996.  

  18. Wang, S.1; Ma, X. B.1; Yuan, X. H.; Yu, B.*; Xu, Y. C.*; Liu, H. M.*, Discovery of new [1,2,4] triazolo[1,5-a]pyrimidine derivatives that Kill gastric cancer cells via the mitochondria pathway. Eur. J. Med. Chem.2020, 203, 112630.

  19. Lu, N.1; Huo, J. L.1; Wang, S.1; Yuan, X. H.; Liu, H. M.*, Drug repurposing: discovery of troxipide analogs as potent antitumor agents. Eur. J. Med. Chem.2020, 202, 112471.

  20. Shi, X. J.1; Wang, S.1; Li, X. J.1; Yuan, X. H.; Cao, L. J.; Yu, B.*; Liu, H. M.*, Discovery of tofacitinib derivatives as orally active antitumor agents based on the scaffold hybridization strategy. Eur. J. Med. Chem.2020, 203, 112601.  

  21. Yuan, X. H.1; Wang, S.1; Cheng, J. L.; Yu, B.*; Liu, H. M.*, HFIP-promoted catalyst-free cascade reactions for the synthesis of biologically relevant 3,3-di(indolyl)indolin-2-ones from indoles and isatins. Chin. Chem. Lett. 2020, 31 (9), 2465-2468.

  22. Wang, S.1; Zhao, L. J.1; Shi, X. J.1; Ding, L. N.1; Yang, L. L.; Wang, Z. Z.; Shen, D. D.; Tang, K.; Li, X. J.; Mamun, M.; Li, H. J.; Yu, B.*; Zheng, Y. C.*; Wang, S. M.*; Liu, H. M.*, Development of highly potent, selective, and cellular active triazolo[1,5-a]pyrimidine-based inhibitors targeting the DCN1-UBC12 protein-protein interaction. J. Med. Chem.2019, 62 (5), 2772-2797.  

  23. He, P. X.1; Niu, S. H.1; Wang, S.1; Shi, X. J.; Feng, S. Q.; Du, L. N.; Zhang, X. Y.; Ma, Z. L.; Yu, B.*; Liu, H. M.*, Discovery of WS-157 as a highly potent, selective and orally active EGFR inhibitor. Acta. Pharm. Sin. B 2019, 9 (6), 1193-1203.  

  24. Wang, S.1; Li, Z. R.1; Suo, F. Z.; Yuan, X. H.; Yu, B.*; Liu, H. M.*, Synthesis, structure-activity relationship studies and biological characterization of new [1,2,4]triazolo[1,5-a]pyrimidine-based LSD1/KDM1A inhibitors. Eur. J. Med. Chem.2019, 167, 388-401.

  25. Li, Z. R.1; Wang, S.1; Yang, L.; Yuan, X. H.; Suo, F. Z.; Yu, B.*; Liu, H. M.*, Experience-based discovery (EBD) of aryl hydrazines as new scaffolds for the development of LSD1/KDM1A inhibitors. Eur. J. Med. Chem. 2019, 166, 432-444.

  26. Wang, S.1; Zhao, L. J.1; Zheng, Y. C.; Shen, D. D.; Miao, E. F.; Qiao, X. P.; Zhao, L. J.; Liu, Y.; Huang, R.; Yu, B.*; Liu, H. M.*, Design, synthesis and biological evaluation of [1,2,4]triazolo[1,5-a]pyrimidines as potent lysine specific demethylase 1 (LSD1/KDM1A) inhibitors. Eur. J. Med. Chem. 2017, 125, 940-951.


地址:上海市杨浦区淞沪路2005号复旦大学江湾校区化学楼   邮编:200438   电话:86-21-31242791
版权所有 © 复旦大学化学系 2014     技术支持:维程互联